OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
504A$680.0055

Innovacell Inc

PharmaceuticalsVerified

Innovacell Inc's capital structure is characterized by a high level of debt, with long-term debt amounting to ¥5,196,177,000 and total liabilities exceeding total assets by ¥630,254,000. The company's liquidity position is mixed, with a current ratio of 10.4, indicating strong short-term liquidity, but a negative net cash position after subtracting total debt. The company's market capitalization is ¥30,667,145,920, with a market price of ¥680 per share. Profitability metrics for Innovacell Inc are weak, with a net loss of ¥2,855,123,000 and an operating loss of ¥2,231,686,000. The return on equity is 4.53%, which is relatively low given the company's negative equity position, and the return on assets is -0.56%, indicating poor asset utilization. These figures suggest that the company is not generating sufficient returns to justify its capital structure or asset base. The company's revenue is not disclosed, and there is no information on geographic or segmental revenue concentration. However, the lack of revenue data makes it difficult to assess the company's exposure to different markets or product lines. In terms of growth trajectory, Innovacell Inc is currently experiencing a decline, with a net loss and negative operating cash flow. The company's capital expenditures are relatively low at ¥52,599,000, which may indicate a focus on cost control rather than expansion. The outlook for the company is uncertain, with no clear indication of future revenue growth or profitability improvement. Risk factors for Innovacell Inc include a high level of debt and a negative equity position, which could lead to financial distress if the company is unable to generate positive cash flows. The company's liquidity risk is medium, and the potential for dilution is low, as there is no indication of share issuance or other dilutive events. The company's risk assessment highlights the negative net cash position after subtracting total debt as a key flag. Recent events and filings for Innovacell Inc are not detailed in the provided data. However, the company's financial performance and capital structure suggest that it may be facing significant challenges in the near term. The lack of revenue data and the absence of detailed segmental or geographic information further complicate the assessment of the company's strategic position.

30-day price · 504A-132.00 (-15.7%)
Low$591.00High$874.00Close$710.00As of22 May, 00:00 UTC
Profile
CompanyInnovacell Inc
Ticker504A.T
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Innovacell Inc is a biotechnology company focused on pharmaceuticals and medical research, primarily generating revenue through the development and commercialization of innovative cell-based therapies.

Classification. Innovacell Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a classification confidence of 0.92.

Innovacell Inc's capital structure is characterized by a high level of debt, with long-term debt amounting to ¥5,196,177,000 and total liabilities exceeding total assets by ¥630,254,000. The company's liquidity position is mixed, with a current ratio of 10.4, indicating strong short-term liquidity, but a negative net cash position after subtracting total debt. The company's market capitalization is ¥30,667,145,920, with a market price of ¥680 per share. Profitability metrics for Innovacell Inc are weak, with a net loss of ¥2,855,123,000 and an operating loss of ¥2,231,686,000. The return on equity is 4.53%, which is relatively low given the company's negative equity position, and the return on assets is -0.56%, indicating poor asset utilization. These figures suggest that the company is not generating sufficient returns to justify its capital structure or asset base. The company's revenue is not disclosed, and there is no information on geographic or segmental revenue concentration. However, the lack of revenue data makes it difficult to assess the company's exposure to different markets or product lines. In terms of growth trajectory, Innovacell Inc is currently experiencing a decline, with a net loss and negative operating cash flow. The company's capital expenditures are relatively low at ¥52,599,000, which may indicate a focus on cost control rather than expansion. The outlook for the company is uncertain, with no clear indication of future revenue growth or profitability improvement. Risk factors for Innovacell Inc include a high level of debt and a negative equity position, which could lead to financial distress if the company is unable to generate positive cash flows. The company's liquidity risk is medium, and the potential for dilution is low, as there is no indication of share issuance or other dilutive events. The company's risk assessment highlights the negative net cash position after subtracting total debt as a key flag. Recent events and filings for Innovacell Inc are not detailed in the provided data. However, the company's financial performance and capital structure suggest that it may be facing significant challenges in the near term. The lack of revenue data and the absence of detailed segmental or geographic information further complicate the assessment of the company's strategic position.
Key takeaways
  • Innovacell Inc has a high level of debt and a negative equity position, indicating significant financial risk.
  • The company's profitability is weak, with a net loss and negative operating cash flow.
  • Liquidity is strong in the short term, but the company's negative net cash position after subtracting total debt is a key risk.
  • The company's growth trajectory is uncertain, with no clear indication of future revenue growth or profitability improvement.
  • The lack of detailed revenue and segmental data makes it difficult to assess the company's strategic position and market exposure.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is negative due to its current net loss and operating loss.",
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$0.00
Gross profit
Operating income-$2.23B
Net income-$2.86B
R&D
SG&A
D&A
SBC
Operating cash flow-$2.00B
CapEx-$52.6M
Free cash flow-$2.84B
Total assets$5.09B
Total liabilities$5.72B
Total equity-$630.3M
Cash & equivalents$4.10B
Long-term debt$5.20B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$0.00-$2.23B-$2.86B-$2.84B
FY-1$0.00-$1.87B-$2.39B-$2.35B
FY-2$0.00-$1.86B-$2.00B-$2.01B
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$5.09B-$630.3M$4.10B
FY-1$2.83B-$1.96B$1.96B
FY-2$2.40B-$1.74B$1.10B
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0-$2.00B-$52.6M-$2.84B
FY-1-$1.30B-$12.0M-$2.35B
FY-2-$1.41B-$61.5M-$2.01B
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$0.00-$723.8M-$953.1M
FQ-1$0.00-$651.0M-$760.5M
FQ-2$0.00-$534.8M-$862.6M
FQ-3-$1.22B
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$12.88B$10.19B$11.65B
FQ-1$5.09B-$630.3M$4.10B
FQ-2$5.56B$316.1M$4.51B
FQ-3$2.96B-$2.09B$2.00B
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1-$2.00B-$52.6M
FQ-2
FQ-3-$1.02B-$23.6M-$1.22B
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$680.00
Market cap$30.67B
Enterprise value$31.76B
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book-$630.3M
Net cash-$1.09B
Current ratio10.4
Debt/Equity-8.2
ROA-56.1%
ROE4.5%
Cash conversion70.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
Metric504AActivity
Op margin18.2% medp25 18.2% · p75 24.6%
Net margin14.7% medp25 11.7% · p75 28.1%
Gross margin19.7% medp25 19.7% · p75 39.8%
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue4.9% medp25 4.2% · p75 6.3%
Debt / equity-824.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-25 00:37 UTCJob: edb6ec88